Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Montanide ISA 51 + P10s-PADRE |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Montanide ISA 51 | ||||
P10s-PADRE | P10s-PADRE is a peptide vaccine comprised of a carbohydrate mimetic-peptide (P10s) and a pan-T-cell epitope (PADRE), which mimics the ganglioside G2 and LeY antigens, thereby potentially inducing the production of antibodies and leading to reduced cell viability and increased apoptosis (PMID: 29228761, PMID: 32582547). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02229084 | Phase Ib/II | Montanide ISA 51 + P10s-PADRE P10s-PADRE | Vaccination of High Risk Breast Cancer Patients | Completed | USA | 0 |
NCT02264236 | Phase Ib/II | Montanide ISA 51 + P10s-PADRE | Vaccination of Advanced-Stage Lung Cancer Patients | Withdrawn | USA | 0 |
NCT02938442 | Phase II | Montanide ISA 51 + P10s-PADRE | Vaccination of Triple Negative Breast Cancer Patients | Completed | USA | 0 |